What You Should Know:
- Veeva Systems has announced a new collaboration with Amgen, a global leader in biotechnology, to advance clinical trial innovation.
- Amgen will use the Veeva Clinical Platform to find and implement efficiencies across its clinical trial processes.
Connected Platform for Clinical Development
The Veeva Clinical Platform is a complete and connected platform that covers clinical operations and data applications. This end-to-end platform includes
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Cleveland Clinic and Dyania Health Partner to Accelerate Clinical Trial Recruitment with AI
What You Should Know:
- Cleveland Clinic and Dyania Health have announced a collaboration to integrate Dyania's Synapsis™ AI platform across Cleveland Clinic’s clinical research enterprise.
- The partnership, which follows successful pilot programs in cardiology, oncology, and neurology, aims to accelerate clinical trial recruitment by using medically trained large language models (LLMs) to speed up and scale patient identification for research studies. The ultimate goal is to provide more
Read More
EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization
What You Should Know:
- EVERSANA and Waltz Health have announced a merger valued at $6B to form a unified healthcare platform that will redefine pharmaceutical commercialization and patient access.
- The merger combines Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model with EVERSANA’s global commercialization services. The new organization aims to deliver a next-generation approach to drug access and value in the U.S. healthcare system, particularly
Read More
Eli Lilly’s Oral GLP-1 Orforglipron Successful in Third Phase 3 Trial
What You Should Know:
- Eli Lilly and Company has announced positive topline results from its Phase 3 ATTAIN-2 trial, which evaluated orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes.
- All three doses of the drug met the primary and all key secondary endpoints, showing significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors over 72 weeks.
Significant Weight Loss and
Read More
AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B
What You Should Know:
- AbbVie and Gilgamesh Pharmaceuticals Inc. have announced a definitive agreement for AbbVie to acquire Gilgamesh's lead investigational candidate, bretisilocin, which is in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
- The deal is valued at up to $1.2B, which includes an upfront payment and development milestones. As part of the acquisition, Gilgamesh will spin off a new entity that will
Read More
Ginkgo, Tangible & Inductive Bio Launch AI-Powered Lab-in-the-Loop Drug Discovery
What You Should Know:
- Ginkgo Bioworks has announced a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven "lab-in-the-loop" drug discovery more accessible to the industry.
- The collaboration combines high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into one seamless, integrated service. This is designed to help scientists discover better drugs with fewer resources by delivering
Read More
OSPRI Launches as Vertically-Integrated Biotech Company with $30M
What You Should Know:
- Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI, a new biotechnology company specializing in polymerase chain reaction (PCR)-based infectious disease detection.
- The merger creates one of the world's first fully vertically-integrated molecular testing platforms.
Addressing Cost and Complexity in PCR Testing
OSPRI will develop and deliver advanced tools to improve access to high-quality
Read More
Ryght AI Announces Partnership with Biorasi to Transform Feasibility Accuracy in Clinical Trials
What You Should Know:
- Ryght AI, an AI clinical trial developer, today announced a partnership with Biorasi, a global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies.
- The collaboration will bring advanced, AI-driven feasibility capabilities to biotech and biopharma sponsors.
Redefine Clinical Trial Feasibility with AI Digital Twin Technology
Ryght AI is reshaping clinical research through a next-generation platform
Read More
FemTech: Gameto Secures $44M to Advance Stem Cell Therapy for Infertility and Menopause
What You Should Know:
- Gameto, a clinical-stage biotechnology company focused on reproductive health secures $44M in Series C funding, bringing its total capital raised to a leading $127M.
- The funding, led by Overwater Ventures with participation from multiple investors including Insight Partners and RA Capital, will support the completion of the ongoing Phase 3 trial for its lead program, Fertilo.
Fertilo: A Paradigm Shift in IVF
Fertilo is a novel therapy designed to
Read More
Garden Launches BLOOM to Make AI Drug Design IP-Aware in Real Time
What You Should Know:
- Garden has announced the launch of BLOOM (Branching Lookup Optimized for Organic Molecules), a Markush structure search engine designed to give AI drug-design teams near-instant verification of small-molecule intellectual property (IP) landscapes.
- As AI models accelerate the pace of molecule generation, the critical bottleneck has shifted from discovery to due diligence—ensuring that a new candidate isn't already patented. BLOOM eliminates this bottleneck,
Read More
